mHealth Diabetes App Launches in U.S. to Transform Disease Management in World’s Largest Market

Dario app sets new economic landscape for diabetes management

NEW YORK, NY / ACCESSWIRE / March 30, 2016 / Americans living with diabetes can ditch their clunky traditional blood glucose meters and step into the digital age with the Dario™ Diabetes Management Solution. The platform technology was launched this week in the U.S. by LabStyle Innovations (DRIO), following FDA clearance in December. This includes an all-in-one smart meter that plugs directly into smartphones coupled with a robust real-time mobile app that allows users to track and monitor data such as blood glucose measurements, carbs and insulin intake, as well as physical activity directly on their mobile devices. Users can share the data with their family and medical staff, altering the economics of one of the most costly diseases in America.

Smartphones have totally cannibalized markets for cameras and navigation devices. We believe healthcare devices including glucose monitors are next. 2016 has been named the year that will bring disease management into the digital age. Look to mHealth leader LabStyle as smartphones become medical monitoring devices.

Digital tech meets healthcare, creating a near-term revenue forecast for companies in the market of $32.4 billion, according to Goldman Sachs. The investment bank’s report about the digital healthcare revolution says the cost of chronic diseases to the U.S. healthcare system is $1.1 trillion.

Better disease management with digital devices like the Dario can hugely impact outcomes for patients and reduce costs for those paying healthcare bills. One recent study published in a medical journal estimates that mobile monitoring of diabetes can slash diabetes management costs 50% by reducing the incidence of hospitalization time and emergency care.

Dario’s U.S. success is sure to propel this innovative young mHealth company into higher prominence, revenues and profits. The U.S. is the largest addressable market in the world for blood glucose monitoring.

I’ve written about LabStyle in the past and diabetes is just its first target market. With its proven ability to create mHealth products, get regulatory approvals, get reimbursement and launch into markets around the globe, LabStyle will pursue other multi-billion-dollar chronic disease management indications. Armed with issued patents covering the testing of a range of bodily and non-bodily fluids, this platform mobile technology addresses vast markets.

Dario is now selling direct-to-consumers through LabStyle’s U.S. website, usa.mydario.com/shop. The company reported it will augment sales through numerous non-exclusive third party distributors and medical equipment suppliers.

Changing market dynamics will benefit LabStyle and its investors with the company well positioned to become the dominant player in the U.S.

RAY DIRKS Research suggests that Readers/Investors place no more than 1% of the funds they devote to common stocks in any one issue. It’s best to diversify.

About Ray Dirks

Ray Dirks came to Wall Street with Goldman, Sachs & Co. in 1963 where he was established as the leading insurance stock analyst dealing with institutional investors and high -net worth investors both in the U.S. and internationally.

In 1973 Ray uncovered the biggest Ponzi scheme of the 20th century, the Equity Funding fraud. Over the years Ray has expanded his stock market research to include Healthcare Stocks and Special Situations. Ray has written two books, “The Great Wall Street Scandal” and “Heads You Win, Tails You Win”, published by McGraw-Hill and Bantam Books respectively. He continues to provide research to institutions and individuals, and he manages money for some individual investors.

Media Contact:

Jackie Rodriguez
646-430-5783

SOURCE: RAY DIRKS Research

ReleaseID: 438257